Next to mediating methotrexate resistance, loss of FPGS is a known mechanism of resistance towards 5-FU treatment in CRC cells (Sohn et al, 2004), which may uncover a vulnerability for C1 treatment. The gene discussed is FPGS; the disease is colorectal carcinoma.